Zhengye Biotechnology regains Nasdaq bid price compliance

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) said on August 6, 2026 that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company received a compliance letter from The Nasdaq Stock Market LLC on August 5, 2026, under Nasdaq Listing Rule 5550(a)(2). The company says its shares continue to be listed on The Nasdaq Capital Market under the ticker ZYBT.

The compliance is narrow. Nasdaq had notified the company on May 29, 2026 that the closing bid price of its Class A ordinary shares had been below $1.00 for 30 consecutive business days. The letter then found that the closing bid price had been at or above $1.00 for the last 10 consecutive business days, from July 20, 2026 to August 4, 2026. The company met the test the rule sets, but the test covers a short stretch of trading.

What the release does not explain

The release does not say what moved the share price above $1.00 in July 2026. It gives no closing prices for the window, no trading volume and no corporate step taken to lift the price. The release gives no explanation for the move.

The release also states no plan for keeping the price above $1.00 and does not say what the company would do if the price fell back below the threshold.

The company behind the listing

The release describes Zhengye as a veterinary vaccine manufacturer engaged in research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccines in China. The release says the operating entity, Jilin Zhengye Biological Products Co., Ltd., has more than 20 years in the business and 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry and dogs. Its products are available in 29 provincial regions across China and are exported to Vietnam, Pakistan and Egypt. It has three veterinary vaccine production floors with 13 production lines. Those are the company's own descriptions.

The company's annual report for 2025, filed April 28, 2026, describes Class A and Class B ordinary shares outstanding. It reports 10,965,000 Class A ordinary shares and 18,760,000 Class B ordinary shares outstanding at the date of the report. The release refers only to the Class A shares when it describes the bid price, and it does not explain the relationship between the two classes.

The numbers behind the price

The annual report's figures show a company whose results turned down sharply in one year. Revenue was $16.6 million for 2025, against $25.5 million for 2024. The company reports a net loss of $10.0 million for 2025, after net income of $1.6 million for 2024. Research and development expense rose to $2.6 million from $1.8 million.

Cash provided by operations fell to $1.9 million for 2025 from $5.6 million for 2024. Year-end cash and cash equivalents rose to $7.2 million from $2.5 million. Year-end cash is the one figure here that moved opposite to the operating results.

What the compliance settles and what it does not

The compliance restores the company to the bid price standard for now. It does not change the 2025 loss, the decline in revenue or the narrower operating cash inflow.

The release sets out the rule and the result. It gives neither the reason for the price move nor any plan for keeping the stock above the minimum.

Report an error

Companies in this story

ZYBTZhengye Biotechnology Holding LimitedNASDAQ · ChinaOpen the starter desk